Aptose Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>AB</div>
APTO -- USA Stock  

USD 5.48  0.27  5.18%

Aptose Bioscns Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 390.36 Million. Tangible Asset Value is expected to rise to about 124.7 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (23.7 M). Aptose Bioscns is scheduled to announce its earnings today. The next earnings report is expected on the 4th of May 2021. As some conservatives are trying to avoid healthcare space, we'll outline Aptose Bioscns a little further and explain its current market possibilities. What exactly are Aptose Bioscns shareholders getting in April? The company moves slightly opposite to the market. We can now inspect Aptose as a potential investment option for your portfolios.
Published over three weeks ago
View all stories for Aptose Bioscns | View All Stories
Check the odds of Aptose Bioscns (NASDAQ:APTO) to slide in April
We provide trade advice to complement the prevailing expert consensus on Aptose Bioscns. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Aptose Bioscns income statement, its balance sheet, and the statement of cash flows. Potential Aptose Bioscns investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Aptose Bioscns investors may use each financial statement separately, they are all related. The changes in Aptose Bioscns's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aptose Bioscns's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Aptose Bioscns fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Aptose Bioscns performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Aptose Bioscns shares is the value that is considered the true value of the share. If the intrinsic value Aptose is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Aptose Bioscns.
Please read more on our fundamental analysis page.

What is Aptose Asset Breakdown?

Aptose Bioscns reports assets on its Balance Sheet. It represents the amount of Aptose resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Aptose volatility, please check the breakdown of all its fundamentals

Are Aptose Bioscns Earnings Expected to grow?

The future earnings power of Aptose Bioscns involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Aptose Bioscns factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Aptose Bioscns stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Aptose expected earnings.

Aptose Bioscns Gross Profit

Aptose Bioscns Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Aptose Bioscns previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Aptose Bioscns Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Acquisition by Bejar Rafael of 343000 shares of Aptose Biosciences subject to Rule 16b-3

Legal trades by Aptose Bioscns insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Aptose insider trading alert for grant of employee stock option (right to buy) by Bejar Rafael, Sr. VP Chief Medical Officer, on 6th of January 2021. This event was filed by Aptose Biosciences Inc with SEC on 2021-01-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Aptose Bioscns

Many companies such as Aptose Bioscns have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of Aptose is distributed among investors.

Ownership Allocation

Aptose Bioscns retains a total of 88.86 Million outstanding shares. Over half of Aptose Bioscns outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Aptose Bioscns. Please watch out for any change in the institutional holdings of Aptose Bioscns as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
Retail Investors42.27

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aptose Bioscns has an asset utilization ratio of 128.91 percent. This suggests that the company is making $1.29 for each dollar of assets. An increasing asset utilization means that Aptose Bioscns is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
122.5 M
Current Assets122.55 Million98.3
Assets Non Current2.12 Million1.7

Can Aptose Bioscns build up on the latest rise?

Latest Jensen Alpha is up to 0.06. Price may slide again. Aptose Bioscns exhibits very low volatility with skewness of 0.08 and kurtosis of 0.1. However, we advise investors to further study Aptose Bioscns technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Aptose Bioscns' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Aptose Bioscns' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Bottom Line

Whereas many other companies in the biotechnology industry are either recovering or due for a correction, Aptose may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor exit any shares of Aptose Bioscns at this time. The Aptose Bioscns risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aptose Bioscns.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Aptose Bioscns. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com